The major factors for the growth of the colorectal cancer screening market include the advent of efficacious genetic tests, an increase in the prevalence of colorectal cancer, and increasing cancer prevention initiatives.
Most of the Colorectal Cancer (CRC) cases exhibit familial clustering, which means that tens of thousands of individuals have a disease with a potentially definable genetic component. The risk of CRC is higher in people with a strong family history of colorectal cancer, i.e., inherited colon cancer syndromes. The genetic tests developed for colon cancer include hereditary nonpolypsis colon cancer (HNPCC) test, familial adenomatous polyposis (FAP) test, etc. Genetic testing for colon cancer creates better opportunities for early diagnosis. For instance, the most common genetic changes related to colon cancer are familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). These genetic changes could be identified at a very early age, less than 40 years through genetic testing. If these medical screenings are employed, the number of colon cancer cases found in the early stages may increase. Also, gene therapies to alter these mutations are likely to be developed. According to a research article published in 2017, “Colorectal cancer screening: An updated review of the available options”, it was estimated that colon cancer incidence and mortality are declining over the past decade, owing to the adoption of effective screening methods, like Fecal DNA test and Blood DNA test. The increasing awareness about genetic screening methods and advantages for undergoing these tests (not only for early detection and treatment, but also for the removal of precancerous cells, which are much cheaper than the usual run of chemotherapy) are driving the colorectal cancer screening market.
Key Market Trends
Colonoscopy is Expected to Dominate the Market
For over a decade, colonoscopy has been the preferred modality for both CRC screening and prevention. Colonoscopy represents a very important diagnostic modality for screening for colorectal cancer, because it has the ability to both detect and effectively remove pro-malignant and malignant lesions.
Moreover, the colorectal cancer inceidence is expected to incerase in future. As per 2018 report by the International Agency for Research on Cancer, the number of cases of the cancer are exepcted to rise from 1.1 million to over 1.5 million by 2030. As colonoscopy is the preferred diagnostic screening test for the cancer, the demand for colonoscopy wi;; rise with increasing incidence of cancer. This will also boost the market growth.
North America is Expected to Dominate the Market
The United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. Additionally, Mexico is a developing nation with the benefit of being neighbor to the US. This allows many companies to penetrate in Mexico as well. This helps the growth in the region.
The market studied is a moderately consolidated market, owing to the presence of many small and large market players. Some of the market players are Abbott Laboratories, Clinical Genomics Technologies Pty Ltd, Epigenomics Inc., Exact Sciences Corporation, F. Hoffmann-La Roche AG, Hemosure Inc., Novigenix SA, Quidel Corporation, Siemens Healthcare Private Limited, and Sysmex Corporation.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support